A Blood Test Identifies Schizophrenia Biomarkers Related To Diagnosis & Treatment

A new blood test can identify biomarkers that can measure the future risk of schizophrenia and current severity. The test results can be used to match individuals to treatments likely to be most effective for their biology, such as clozapine and risperidone, as well as lithium, fluoxetine, valproate, and the nutraceuticals omega-3 fatty acids and magnesium. The test is anticipated to be available later in 2024 from MindX Sciences, a spin-out company by the Indiana University School of Medicine.

The development of the blood test builds on the researchers’ previous work on blood biomarkers for other psychiatric disorders . . .